While p16INK4a is a specific inhibitor of D-CDK4/6 kinases that promotes G1 phase arrest by RB1 activation, ARF has multiple targets through which it elicits cell cycle arrest, apoptosis, autophagy, and/or other tumor suppressive biological changes. Here, CDKN2A is linked to neoplasm.